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Summary
Background The International Carotid Stenting Study (ICSS) of stenting and endarterectomy for symptomatic carotid 
stenosis found a higher incidence of stroke within 30 days of stenting compared with endarterectomy. We aimed to 
compare the rate of ischaemic brain injury detectable on MRI between the two groups. 
Methods Patients with recently symptomatic carotid artery stenosis enrolled in ICSS were randomly assigned in a 
1:1 ratio to receive carotid artery stenting or endarterectomy. Of 50 centres in ICSS, seven took part in the MRI substudy. 
The protocol speciﬁ ed that MRI was done 1–7 days before treatment, 1–3 days after treatment (post-treatment scan), 
and 27–33 days after treatment. Scans were analysed by two or three investigators who were masked to treatment. The 
primary endpoint was the presence of at least one new ischaemic brain lesion on diﬀ usion-weighted imaging (DWI) on 
the post-treatment scan. Analysis was per protocol. This is a substudy of a registered trial, ISRCTN 25337470.
Findings 231 patients (124 in the stenting group and 107 in the endarterectomy group) had MRI before and after 
treatment. 62 (50%) of 124 patients in the stenting group and 18 (17%) of 107 patients in the endarterectomy group 
had at least one new DWI lesion detected on post-treatment scans done a median of 1 day after treatment (adjusted 
odds ratio [OR] 5∙21, 95% CI 2∙78–9∙79; p<0∙0001). At 1 month, there were changes on ﬂ uid-attenuated inversion 
recovery sequences in 28 (33%) of 86 patients in the stenting group and six (8%) of 75 in the endarterectomy group 
(adjusted OR 5·93, 95% CI 2·25–15·62; p=0·0003). In patients treated at a centre with a policy of using cerebral 
protection devices, 37 (73%) of 51 in the stenting group and eight (17%) of 46 in the endarterectomy group had at least 
one new DWI lesion on post-treatment scans (adjusted OR 12·20, 95% CI 4·53–32·84), whereas in those treated at a 
centre with a policy of unprotected stenting, 25 (34%) of 73 patients in the stenting group and ten (16%) of 61 in the 
endarterectomy group had new lesions on DWI (adjusted OR 2·70, 1·16–6·24; interaction p=0·019). 
Interpretation About three times more patients in the stenting group than in the endarterectomy group had new 
ischaemic lesions on DWI on post-treatment scans. The diﬀ erence in clinical stroke risk in ICSS is therefore unlikely 
to have been caused by ascertainment bias. Protection devices did not seem to be eﬀ ective in preventing cerebral 
ischaemia during stenting. DWI might serve as a surrogate outcome measure in future trials of carotid interventions.
Funding UK Medical Research Council, the Stroke Association, Sanoﬁ -Synthélabo, European Union, Netherlands 
Heart Foundation, and Mach-Gaensslen Foundation.
Introduction
Percutaneous stenting is an alternative to endarterectomy 
for the treatment of internal carotid artery stenosis. The 
International Carotid Stenting Study (ICSS) recently com-
pleted random assignment of patients with symptomatic 
carotid stenosis to stenting or endarterectomy, and the 
interim results have been published.1 The risk of procedural 
stroke, myocardial infarction, or death within the ﬁ rst 
120 days after randomisation was signiﬁ cantly higher with 
stenting than with surgery (intention-to-treat analysis 
8·5% vs 5·2%, p=0·006), as was the risk within 30 days of 
treatment in the per-protocol analysis (7·4% vs 4·0%, 
p=0·003). This diﬀ erence was mainly caused by a higher 
number of non-disabling strokes in the stenting group 
(36 vs 11 within 30 days of treatment); the rate of disabling 
stroke or death did not diﬀ er signiﬁ cantly (26 vs 18). 
Clinical follow-up of patients in ICSS was not masked to 
treatment allocation; therefore, there was the possibility of 
potential bias in ascertainment of non-disabling strokes. 
We used multimodal MRI as an additional outcome 
measure of procedural cerebral ischaemia that could be 
analysed without knowledge of treatment allocation. We 
aimed to compare the risk of procedural ischaemia and 
persistent infarction on MRI between patients randomly 
allocated to receive stenting or endarterectomy and to 
investigate the eﬀ ect of cerebral protection devices on the 
risk of ischaemia associated with stenting. 
Methods
Patients
The ICSS-MRI study is a prospective multicentre substudy 
of ICSS. Details of centre and investigator requirements, 
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eligibility criteria, method of random isation, nature of 
interventions, follow-up requirements, and the deﬁ nition 
and assessment of outcome events have been described.1–3 
Brieﬂ y, patients with recently symptomatic, at least 
moderate carotid artery stenosis (≥50% measured 
according to the North American Symptomatic Carotid 
Endarterectomy Trial criteria4) were randomly allocated to 
treatment with stenting or endarterectomy. 
ICSS centres with suﬃ  cient neuroimaging facilities 
were invited to take part in the ICSS-MRI study. All patients 
randomly assigned to treatment in ICSS were eligible to 
participate if they had no contraindications to MRI.
The study was approved by local ethics committees for 
non-UK centres and by the Northwest Multicentre 
Research Ethics Committee in the UK. Patients provided 
written informed consent to undergo MRI when the 
scans were not part of clinical routine. 
Randomisation and masking
Eligible patients were randomly assigned in a 1:1 ratio to 
receive stenting or endarterectomy by use of a 
computerised service provided by the Oxford Clinical 
Trials Service Unit staﬀ  who were not involved in other 
parts of the trial. The allocated treatment was 
communicated to investigators or one of their research 
team by telephone after they provided baseline data of 
the patient. Randomisation was stratiﬁ ed by centre with 
minimisation for sex, age, contralateral occlusion, and 
side of the randomised artery. Investigators were masked 
to the randomisation program. Patients and individuals 
who delivered the interventions were not masked to 
treatment assignment. Patients were followed up, and 
clinical outcome events reported to the central trial oﬃ  ce, 
by independent clinicians who were not masked to 
treatment assignment but who were not directly involved 
in delivering the randomly allocated treatment. 
Adjudication of outcomes was blinded. Apart from the 
trial statistician and the data monitoring committee, all 
ICSS investigators, including the chief investigator, 
remained masked to the results of the trial, including the 
ICSS-MRI study, until after recruitment was completed. 
Procedures
Stents and other devices used for carotid stenting were 
chosen by the treating physician but had to have a 
CE mark. The protocol recommended that a cerebral 
protection device should be used whenever the local 
investigator thought that one could be used safely, but 
this was not mandatory. A combination of aspirin and 
clopidogrel to cover stenting procedures was 
recommended. Use of heparin during the procedure was 
mandatory. Surgeons could use standard or eversion 
endarterectomy. The use of local or general anaesthesia, 
shunts, and patches was at the discretion of the surgeon.
The protocol initially speciﬁ ed MRI scans to take place 
1–3 days before treatment (pretreatment scan), 1–3 days 
after treatment (post-treatment scan), and 27–33 days 
after treatment (1-month follow-up scan). During the 
study, the window for the pretreatment scan was extended 
to 7  days before treatment to allow for more ﬂ exibility. 
Diﬀ usion-weighted imaging (DWI) sequences were used 
at each scan to detect acute ischaemic brain lesions. 
Fluid-attenuated inversion recovery (FLAIR) sequences 
were used at pretreatment scans to measure cerebral 
white matter changes and at 1-month follow-up scans to 
investigate whether acute ischaemic brain lesions led to 
persistent tissue changes. Centres were allowed to use 
scanners with ﬁ eld strengths of 1·5 Tesla or 3 Tesla, as 
long as the same scanner and the same imaging 
parameters were used in both treatment groups (table 1). 
A neurologist and a neuroradiologist, both masked to 
treatment, analysed all scans. Disagreement was resolved 
by consensus or, if no consensus could be reached, a 
third reviewer had the ﬁ nal decision. On each scan, the 
number, vascular territory according to previously 
published templates,5 and volume of hyperintense lesions 
on DWI, signifying acute cerebral ischaemia, were 
measured. Volumes of separate lesions were calculated 
by measuring lesion diameters in three axes, converted 
to mL.6 Lesions were considered separate if there was no 
continuity between them on the same slice as well as on 
adjacent slices. Baseline white-matter changes were 
semiquantitatively assessed on FLAIR sequences of the 
pretreatment scan by use of the sum of the age-related 
white matter changes (ARWMC) score.7 The sites of 
hyperintense lesions on post-treatment DWI sequences 
were investigated for corresponding hyperintense signal 
on FLAIR sequences at 1-month follow-up, signifying 
persistent infarction.
The primary imaging outcome was the presence of any 
new hyperintense DWI lesion on the post-treatment scan 
that was not present on the pretreatment scan. Secondary 
imaging outcome measures were hyperintensity on 
FLAIR images at 1-month follow-up at the site of at least 
one post-treatment DWI lesion that was not present on 
the pretreatment scan; and the presence of any 
Tesla Slice 
thickness 
(mm)
Gap 
thickness 
(mm)
Matrix Field of 
view 
(mm)
Echo time 
(ms)
b* (s/mm²)
Amsterdam 3 3 0 256×256 230 94 1000
Basel 1·5 5 2 128×128 230 105 1000
London 1·5 5 1·5 256×256 230 96 1000
Newcastle 3 4 1 256×256 230 70 2500
Rotterdam 1·5
3
5
5
0
0
256×256
256×256
240
250
85
65
1000
1000
Sheﬃ  eld 1·5 5 1 130×130 240 102 1000
Utrecht 1·5
3
5
5
0
0
128×128
256×256
230
230
79
71
1000
2500
*The b value is a function of diﬀ usion gradient strength, the duration of the gradient, and the interval between 
diﬀ usion gradients. The higher the b value, the stronger the diﬀ usion weighting, with a resulting increase in contrast 
between lesions and normal brain tissue.
Table 1: DWI parameters used at participating centres
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hyperintense DWI lesion at 1-month follow-up that was 
not present on the post-treatment scan.
Statistical analysis
A sample size of at least 100 patients per treatment group 
was chosen on the basis of detecting an increase in the 
proportion of patients with the primary outcome measure 
in the stenting group of two times compared with the 
endarterectomy group at a signiﬁ cance level of 0·05 and 
90% power, assuming 25% of patients in the 
endarterectomy group would have new DWI lesions after 
treatment. SPSS Statistics software version 17.0 was used 
for statistical analysis (SPSS, Chicago, IL, USA).
The primary analysis of MRI outcome measures 
included all patients who completed the allocated 
treatment and who had both the pretreatment scan and 
the post-treatment scan. A secondary sensitivity analysis 
excluded patients whose pretreatment scans were done 
more than 7 days before treatment or whose post-
treatment scans were done more than 3 days after 
treatment. We used binary logistic regression models to 
compare MRI outcome measures between treatment 
groups, adjusted for any signiﬁ cant imbalances in 
baseline characteristics. Interactions between the eﬀ ect 
of treatment on the primary outcome measure and 
selected baseline characteristics (age, sex, type of most 
recent ipsilateral event, presence of a hyperintense DWI 
lesion before treatment, and ARWMC score) were 
investigated, adjusted for any signiﬁ cant imbalances in 
baseline characteristics. 
To assess the eﬀ ect of cerebral protection devices in 
stenting, we separated centres into those with a policy of 
Figure 1: Study proﬁ le
DWI=diﬀ usion-weighted imaging.*Carotid occlusion before scheduled treatment. †Carotid occlusion (n=4), patient was unﬁ t for either procedure (n=1). ‡Suspected 
lung tumour in preoperative investigation (n=1), refused allocated treatment (n=1). §Hypotension. ¶Probable cardiac cause. ||Functional carotid occlusion (n=1) and 
stenosis <50% (n=1). **Problems in getting access to stenosis (n=2) and severe back pain during the procedure (n=1). ††Hypotension. ‡‡Hypotension or 
hypertension (n=3), non-fatal procedural myocardial infarction (n=1), cardiac arrhythmia (n=2), surgical clips with uncertain MRI compatibility used (n=1). 
379 patients randomised
189 allocated to carotid stenting
 1 received best medical therapy only*
 10 MRI contraindicated
 2 did not consent to MRI study
 27 MRI scanner unavailable before treatment
2 DWI not done
5 carotid stenting aborted
 2 received best medical therapy only||
 3 received carotid endarterectomy**
 1 fatal procedural stroke
 1 fatal procedural myocardial infarction
 1 no post-treatment scan for medical reasons††
 1 withdrew consent for post-treatment scan
 12 MRI scanner unavailable after treatment
2 insuﬃcient DWI quality 
 1 fatal procedural stroke 
 7 no post-treatment scan for medical reasons‡‡
 1 withdrew consent for post-treatment scan
 13 MRI scanner unavailable after treatment
1 died before treatment¶
1 withdrew consent for treatment and 
received best medical therapy only
 5 received best medical therapy only†
 2 had carotid stenting‡ 
 9 MRI contraindicated
 1 no pretreatment scan for medical reasons§
 3 did not consent to MRI study
39 MRI scanner unavailable before treatment
190 allocated to carotid endarterectomy
149 had pretreatment scan 131 had pretreatment scan
147 carotid stenting started 129 carotid endarterectomy started
142 carotid stenting completed 129 carotid endarterectomy completed
126 had early post-treatment scan 107 had early post-treatment scan
124 included in primary analysis 107 included in primary analysis
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using such devices wherever possible and those with a 
policy of using mainly unprotected stenting, and tested 
for an interaction between centre policy and treatment 
eﬀ ect. To take into account the fact that centres with a 
policy of protected stenting did not use cerebral protection 
devices in every patient and that the devices were used in 
some patients at centres with a policy of unprotected 
stenting, we also did a direct comparison between 
patients treated with protection versus those treated 
without in the stenting group, adjusted for any signiﬁ cant 
imbalances in baseline characteristics between groups. 
A non-randomised exploratory comparison of the total 
lesion number and total lesion volume was done in the 
subset of patients with new DWI lesions on the post-
treatment scan by use of Mann-Whitney tests. 
This is a substudy of a registered trial, ISRCTN 
25337470.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. LHB, MMB, and STE had full 
access to all data in the study and had ﬁ nal responsibility 
to submit the manuscript for publication. 
Results
In ICSS, 1713 patients were randomly allocated to stenting 
(n=855) or endarterectomy (n=858) between May, 2001, 
and October, 2008. Seven centres used the ICSS-MRI 
study protocol: ﬁ ve had a policy of using cerebral 
protection devices during stenting and two had a policy of 
unprotected stenting. In these seven centres, 189 patients 
were randomly assigned to stenting and 190 patients to 
endarterectomy (ﬁ gure 1). 124 patients in the stenting 
group and 107 patients in the endarterectomy group were 
included in the primary analysis. Figure 1 shows the 
reasons for exclusion and incomplete MRI. In the primary 
analysis population, the pretreatment scan was done 
more than 7 days before treatment in one patient in the 
stenting group (11 days) and in 14 patients in the 
endarterectomy group (maximum 29 days [median 9, 
IQR 8–16]). The post-treatment scan was done more 
than 3  days after treatment in ﬁ ve patients in the 
stenting group (maximum 6 days [5, 4–6]), and in eight 
patients in the endarterectomy group (maximum 8 days 
[5, 4–7]). In 203 patients (118 in the stenting group and 
85 in the endarterectomy group), both pretreatment 
and post-treatment scans were done within the speciﬁ ed 
time limits.
Demographic, clinical and MRI baseline characteristics 
did not diﬀ er substantially between the two groups 
(table 2); however, the interval between treatment and the 
post-treatment MRI scan was longer in the endarterectomy 
group (p=0·008). Baseline characteristics were similar to 
those of patients in the main ICSS trial who were not 
included in this MRI substudy, with the exception of 
higher systolic blood pressure at randomisation in 
patients in the MRI substudy than in the other patients 
(mean 156 mm Hg [SD 27] vs 144 mm Hg [23]), p<0·0001).1 
In a post-hoc analysis, systolic blood pressure did not 
predict the occurrence of new DWI lesions after treatment 
(unadjusted OR 1·00 [95% CI 0·99–1·01], p=0·682; OR 
adjusted for treatment 1·00 [0·99–1·01], p=0·703).
11 (9%) of 124 patients in the stenting group had any 
procedural stroke or death (ie, occurring within 30 days 
of treatment) compared with ﬁ ve (5%) of 107 in the 
endarterectomy group (p=0·30, table 3). Although there 
were no fatal strokes, one sudden cardiac death occurred 
25 days after stenting. 13 patients (10%) in the stenting 
group and three (3%) in the endarterectomy group had 
procedural transient ischaemic attack or ischaemic stroke 
(OR 4∙06, 95% CI 1∙20–13∙63, p=0·035). 
Carotid 
stenting
(n=124)
Carotid 
endarterectomy
(n=107)
Age (years) 70·5 (9·4) 69·5 (8·8)
Men 87 (70%) 76 (71%)
Vascular risk factors
History of hypertension 85 (69%) 74 (69%)
History of diabetes 24 (19%) 24 (22%)
History of hypercholesterolaemia 78 (63%) 72 (67%)
Smoking (past or present) 94 (76%) 80 (75%)
Coronary heart disease 30 (24%) 21 (20%)
Peripheral artery disease 22 (18%) 15 (14%)
Systolic blood pressure at randomisation (mm Hg) 156·3 (26·0) 155·7 (28·3)
Total cholesterol at randomisation (mmol/L) 4·8 (1·3) 5·0 (1·3)
Most recent ipsilateral event
Amaurosis fugax 23 (19%) 21 (20%)
Retinal stroke 4 (3%) 1 (1%)
Transient ischaemic attack 42 (34%) 46 (43%)
Hemispheric ischaemic stroke 55 (44%) 39 (36%)
Modiﬁ ed Rankin scale score at randomisation
0 54 (44%) 38 (36%)
1 29 (23%) 29 (27%)
2 31 (25%) 28 (26%)
3 7 (6%) 9 (8%)
4 3 (2%) 3 (3%)
Degree of ipsilateral carotid stenosis at randomisation*
Moderate (50–69%) 17 (14%) 8 (8%)
Severe (70–99%) 107 (86%) 99 (93%)
Contralateral carotid occlusion 8 (6%) 2 (2%)
Interval between most recent ipsilateral event and treatment (days) 37 (14–82) 45 (23–85)
Interval between pretreatment scan and treatment (days) 1 (1–3) 1 (1–3)
Interval between treatment and post-treatment scan (days) 1 (1–1)† 1 (1–2)†
Presence of ischaemic lesion on DWI before treatment 54 (44%) 42 (39%)
ARWMC score 4 (2–7) 4 (2–8)
Interval between treatment and 1-month follow-up scan‡ (days) 33 (30–36) 33 (30–34)
Data are mean (SD), number (%), or median (IQR). ARWMC=age-related white matter changes. 
DWI=diﬀ usion-weighted imaging. *According to NASCET method. †Mann-Whitney test p=0·008. ‡1-month 
follow-up scans were done in 86 patients in the stenting group and in 75 patients in the endarterectomy group.
Table 2: Demographics and baseline characteristics
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62 (50%) of 124 patients in the stenting group had new 
DWI lesions on post-treatment scans compared with 
18 (17%) of 107 patients in the endarterectomy group 
(OR 5·21, 95% CI 2·78–9·79; p<0·0001, adjusted for 
interval between treatment and post-treatment scan; 
table 4). There were non-signiﬁ cant imbalances between 
treatment groups in the proportion of patients with 
hemispheric ischaemic stroke as qualifying event 
(55 [44%] of 124 in the stenting group and 39 [36%] of 107 
in the endarterectomy group, p=0·223) and interval 
between most recent ipsilateral event and treatment 
(median 37 days [IQR 14–82] in the stenting group and 
45 [23–85] in the endarterectomy group, p=0·123; table 2). 
In a post-hoc comparison adjusted for these variables in 
addition to interval between treatment and post-treatment 
scan, the OR for new DWI lesions was 5·30 (95% CI 
2·80–10·05, p<0·0001). In patients who had pretreatment 
and post-treatment scans within the prespeciﬁ ed time 
limits, 58 (49%) of 118 patients in the stenting group and 
15 (18%) of 85 patients in the endarterectomy group had 
new DWI lesions after treatment (adjusted OR 4·84, 
95% CI 2·45–9·55; p<0·0001). 
66 patients were studied in 3 Tesla scanners (37 in the 
stenting group and 29 in the endarterectomy group) and 
165 in 1·5 Tesla scanners. Lesions were detected in 29 
(44%) of 66 patients scanned with 3 Tesla compared with 
51 (31%) of 165 patients scanned with 1·5 Tesla (p=0·06).
In eight of 62 patients with positive DWI after stenting, 
lesions were associated with symptoms of an ischaemic 
hemispheric stroke between initiation of treatment and 
the post-treatment scan, and one patient had an ipsilateral 
retinal stroke before the scan (table 4). In the other 
53 patients with stents and new DWI lesions, no 
ischaemic events happened up to the time of the scan; 
however, one patient had an ischaemic stroke 4 days after 
the scan, and two had transient ischaemic attacks (26 and 
28 days after the scan). In addition, one patient without 
new DWI lesions on the post-treatment scan had a 
transient ischaemic attack 19 days after the scan. In the 
endarterectomy group, three of 18 patients with new 
DWI lesions had ischaemic hemispheric strokes, whereas 
15 did not have any ischaemic events up to the time of 
the scan; however, two patients who did not have any new 
lesions on post-treatment DWI had haemorrhagic strokes 
1 and 3 days after the scan. No hemispheric ischaemic 
event occurred between treatment and the post-treatment 
scan without a corresponding lesion on DWI in any of 
the 231 patients included in the primary analysis.
In patients with hemispheric stroke as the qualifying 
event, 33 (60%) of 55 in the stenting group and four (10%) 
of 39 in the endarterectomy group had new DWI lesions 
on post-treatment scans (adjusted OR 15·04, 95% CI 
4·38–51·67), whereas in those with a retinal ischaemic 
event or transient ischaemic attack as the qualifying 
event, 29 (42%) of 69 in the stenting group and 14 (21%) 
of 68 in the endarterectomy group had new DWI lesions 
(adjusted OR 2·89, 1·34–6·22; interaction p=0·025; 
ﬁ gure 2). In patients treated at a centre with a policy of 
using cerebral protection devices, 37 (73%) of 51 in the 
stenting group and eight (17%) of 46 in the endarterectomy 
group had new DWI lesions on post-treatment scans 
(adjusted OR 12·20, 95% CI 4·53–32·84), whereas in 
those treated at a centre with a policy of unprotected 
stenting 25 (34%) of 73 patients in the stenting group and 
ten (16%) of 61 in the endarterectomy group had new 
lesions on DWI (adjusted OR 2·70, 1·16–6·24; interaction 
p=0·019). Both interactions remained signiﬁ cant after 
adjustment for each other (p=0·040 and p=0·038, 
respectively). In the stenting group, cerebral protection 
Carotid stenting 
(n=124)
Carotid endarterectomy 
(n=107)
OR (95% CI) p*
Any stroke or death 11 (9%) 5 (5%) 1·99 (0·70–5·66) 0·300
All cause death 1 (1%) 0 ·· ··
Any stroke 10 (8%) 5 (5%) 1·79 (0·62–5·17) 0·423
Stroke pathology
Ischaemic 10 (8%) 3 (3%) ·· ··
Haemorrhagic 0 2 (2%) ·· ··
Stroke severity
Non-disabling 7 (6%) 2 (2%) ·· ··
Disabling 3 (2%) 3 (3%) ·· ··
Fatal 0 0 ·· ··
TIA 3 (2%) 0 ·· ··
Ischaemic stroke or TIA 13 (10%) 3 (3%) 4·06 (1·20–13·63) 0·035
Data are number (%). TIA=transient ischaemic attack. *Fisher’s exact test.
Table 3: Clinical outcome within 30 days of treatment
Carotid 
stenting 
(n=124)
Carotid 
endarterectomy 
(n=107)
OR (95% CI) p*
At least one new lesion 62 (50%) 18 (17%) 4·94 (2·67–9·16)†
5·21 (2·78–9·79)‡
<0·0001
<0·0001
Single lesion 18 (15%) 9 (8%) ·· ··
Multiple lesions 44 (35%) 9 (8%) ·· ··
Location of lesions
Ipsilateral carotid circulation only 34 (27%) 14 (13%) ·· ··
Ipsilateral carotid and non-ipsilateral 
(contralateral carotid or vertebrobasilar) 
circulations 
22 (18%) 3 (3%) ·· ··
Non-ipsilateral (contralateral carotid or 
vertebrobasilar) circulations only
6 (5%) 1 (1%) ·· ··
Ischaemic events in patients with new 
DWI lesions§
9 (7%) 3 (3%) ·· ··
Hemispheric stroke 8 (6%) 3 (3%) ·· ··
Retinal infarct 1 (1%) 0 ·· ··
TIA 0 0 ·· ··
None 53 (43%) 15 (14%) ·· ··
Data are number (%). DWI=diﬀ usion-weighted imaging. TIA=transient ischaemic attack. *Logistic regression. 
†Unadjusted. ‡Adjusted for interval between treatment and post-treatment scan. §Events occurring between start of 
treatment and post-treatment scans only. No ischaemic event occurred between the start of treatment and the post-
treatment scan in patients without new DWI lesions.
Table 4: New DWI lesions on post-treatment scans
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devices were used in 47 (92%) of 51 patients enrolled at 
centres with a policy of using protection, and in nine 
(12%) of 73 patients at centres with a policy of unprotected 
stenting. All cerebral protection devices used in the ICSS-
MRI study were of the ﬁ lter type. Compared with patients 
who had stenting without protection, in those who had 
cerebral protection devices a history of hypertension was 
more common (80% vs 59%, p=0·012) and intervals 
between treatment and post-treatment scans were longer 
(median 1 day [IQR 1–2] vs 1 day [1–1], p=0·001). When 
use of cerebral protection devices was compared 
irrespective of centre policy, 38 (68%) of 56 patients who 
had protected stenting and 24 (35%) of 68 patients who 
had unprotected stenting had new DWI lesions after 
treatment (OR 3·28, 1·50–7·20; p=0·003, adjusted for 
hypertension and delay to post-treatment scan).
In patients with new DWI lesions on the post-treatment 
scan, the median number of lesions in patients in the 
stenting group was 3 (IQR 1–9) compared with 2 (1–5) in 
patients in the endarterectomy group (p=0·073). Median 
total lesion volume was 0·17 mL (IQR 0·06–0·58) in the 
stenting group and 0·19 mL (0·06–0·58) in the 
endarterectomy group (p=0·800). In both groups 
combined, median total lesion volume was 9·40 mL 
(IQR 2·26–12·83) in the 11 patients (eight in the stenting 
group and three in the endarterectomy group) with 
corresponding symptoms of ischaemic hemispheric 
stroke and 0·12 mL (0·05–0·40) in the 69 patients (54 in 
the stenting group and 15 in the endarterectomy group) 
with silent lesions (p<0·0001, ﬁ gure 3).
1-month follow-up MRI scans were not done routinely 
at one centre (17 patients in the stenting group and 16 in 
the endarterectomy group). In the other centres, all three 
scans were done in 86 (80%) of 107 patients in the 
stenting group and in 75 (82%) of 91 patients in the 
endarterectomy group. Within this population, 89 (17%) 
of 537 DWI lesions detected at post-treatment scans in 
the stenting group and 18 (53%) of 34 DWI lesions in the 
endarterectomy group had a corresponding hyperintense 
FLAIR signal at follow-up. FLAIR signals were present at 
follow-up at the site of at least one post-treatment DWI 
lesion in 28 patients (33%) in the stenting group and six 
Figure 2: New DWI lesions on post-treatment scans in patient subgroups
Data are numbers of patients (%) with new DWI lesions on post-treatment scans (DWI positive) and total numbers of patients per treatment group. Squares and 
horizontal lines are adjusted odds ratios (OR) and 95% CIs. The diamond represents the overall adjusted OR and 95% CI. All OR and interaction p values are adjusted 
for interval between treatment and post-treatment scan. *Dichotomised at the rounded median age of the study population. DWI=diﬀ usion-weighted imaging. 
ARWMC=age-related white matter changes. 
Carotid stenting
DWI positive, 
n (%)
Total, n
Carotid endarterectomy OR (95% CI) p
DWI positive, 
n (%)
Total, n
10·05 0·2 5 20
Favours carotid stenting Favours carotid endarterectomy
Age*
<71 years 25 (40) 62 9 (17) 52 3·27 (1·34–8·02) 0·187
≥71 years 37 (60) 62 9 (16) 55 8·10 (3·30–19·86) 
 
Sex 
Female 20 (54) 37 5 (16) 31 5·77 (1·78–18·72) 0·593
Male 42 (48) 87 13 (17) 76 4·95 (2·34–10·48)
 
Type of qualifying event
Retinal or TIA 29 (42) 69 14 (21) 68 2·89 (1·34–6·22) 0·025
Hemispheric stroke 33 (60) 55 4 (10) 39 15·04 (4·38–51·67)
   
DWI lesion on pretreatment scan
No 34 (49) 70 10 (15) 65 5·16 (2·24–11·91) 0·853
Yes 28 (52) 54 8 (19) 42 5·02 (1·91–13·22)
ARWMC score on pretreatment scan
0–4 27 (40) 67 10 (16) 63 3·30 (1·41–7·69) 0·272
≥5 35 (61) 57 8 (18) 44 8·47 (3·15–22·78)
Centre policy of using cerebral protection devices
No 25 (34) 73 10 (16) 61 2·70 (1·16–6·24) 0·019
Yes 37 (73) 51 8 (17) 46 12·20 (4·53–32·84)
 
Total 62 (50) 124 18 (17) 107 5·21 (2·78–9·79)
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patients (8%) in the endarterectomy group (adjusted OR 
5·93 [95% CI 2·25–15·62]; p=0·0003; table 5). Six 
patients in the stenting group and one in the 
endarterectomy group had new hyperintense DWI 
lesions on the 1-month follow-up scan.
The two reviewers initially disagreed and reached 
consensus on the presence or absence of hyperintense 
DWI lesions in two of 231 pretreatment scans that were 
included in the primary analysis, eight of 231 post-
treatment scans, and one of 161 scans at 1-month follow-
up. In addition, there was initial disagreement on the 
number of lesions in 25 of the 80 patients who had new 
DWI lesions on post-treatment scans.
Discussion
In this MRI substudy of ICSS, about three times more 
patients had new ischaemic lesions on DWI after stenting 
than after endarterectomy, and the risk of cerebral 
ischaemia was higher among patients undergoing 
stenting with cerebral protection devices than without. 
Non-randomised studies have suggested a higher rate 
of postprocedural ischaemic lesions on DWI after 
stenting compared with endarterectomy:8–16 in a meta-
analysis of these studies the aggregate OR of new 
ischaemic lesions after treatment was 6·71 (95% CI 
4·57–9·87) favouring endarterectomy (ﬁ gure 4). However, 
whether this was because more patients who had high 
cardiovascular risk proﬁ les were assigned to stenting is 
unclear. The OR for DWI lesions in our randomised 
study was very similar, arguing against such a bias.
At most centres in ICSS, patients were sent to 
neurological wards after stenting, whereas patients who 
had endarterectomy were transferred to high-dependency 
units or were sent to surgical wards for care after 
treatment. Thus, non-disabling strokes might have been 
detected more readily among patients who had stenting 
than among those who had endarterectomy. However, 
the results of the ICSS-MRI study conﬁ rm an increased 
risk of cerebral ischaemia associated with stenting in 
comparison with endarterectomy by using a separate, 
blinded assessment of MRI; thus it is unlikely that 
ascertainment bias caused the diﬀ erence in non-disabling 
strokes between the two groups.
Among the 62 patients in the stenting group who had 
new DWI lesions after treatment, 44 (71%) had more than 
one lesion, and 28 (45%) had lesions in the contralateral 
carotid or vertebrobasilar circulation (mostly in addition 
to lesions in the ipsilateral carotid circulation). These 
results support the notion of an embolic pathogenesis of 
cerebral ischaemia.17 Embolism might have happened at 
any stage of the stent procedure, including angiography 
before stenting.18 Thrombotic material or atherosclerotic 
debris dislodged during the stenting procedure seems to 
result in single or multiple small emboli, which might 
manifest as stroke if a large enough volume of eloquent 
brain tissue is aﬀ ected.
The diﬀ erential risk of cerebral ischaemia was modiﬁ ed 
by the type of the most recent ipsilateral event before 
randomisation: the proportion with DWI lesions 
associated with stenting was smaller for patients enrolled 
after a transient ischaemic attack or a retinal ischaemic 
event than for patients who were enrolled after a 
hemispheric stroke. This pattern might have developed 
because patients with strokes have less stable plaques 
compared with those presenting with other ischaemic 
symptoms, a hypothesis that is supported by a histological 
study of symptomatic carotid plaques.19 Thus, increased 
Figure 3: Distribution of DWI lesion volumes on post-treatment scans 
according to whether or not focal neurological deﬁ cits occurred
DWI=diﬀ usion-weighted imaging.
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Carotid stenting 
(n=86)
Carotid endarterectomy 
(n=75)
OR (95% CI) p*
At least one new ischaemic lesion on post-treatment DWI 44 (51%) 10 (13%) ·· ··
New hyperintensity on FLAIR at 1-month follow-up at site of at 
least one post-treatment DWI lesion
28 (33%) 6 (8%) 5·55 (2·15–14·33) 
5.93 (2·25–15·62)
0·0004†
0·0003‡
New ischaemic lesion on DWI at 1-month follow-up not seen on 
post-treatment scan
6 (7%) 1 (1%) 5·55 (0·65–47·19) 0·117†
Data are number (%) or OR (95% CI). Patients with completed pretreatment, post-treatment and 1-month follow-up MRI scans are included. DWI=diﬀ usion-weighted 
imaging. FLAIR=ﬂ uid-attenuated inversion recovery imaging. *Logistic regression. †Unadjusted. ‡Adjusted for interval between treatment and post-treatment scan.
Table 5: MRI ﬁ ndings at 1-month follow-up
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plaque instability might pose a greater risk for cerebral 
embolism with stenting than with endarterectomy.
Five centres participating in the ICSS-MRI study had a 
policy of using ﬁ lter-type cerebral protection devices 
during stenting, whereas at two centres stenting was 
mainly done without protection. The proportion of 
patients with DWI lesions in the stenting group was 
higher when centres used protection than when they did 
not. Our ﬁ ndings seem to contradict systematic reviews 
of observational studies reporting lower rates of stroke 
and ischaemia on DWI with protected than with 
unprotected stenting.20,21 However, these studies either 
compared outcomes after protected stenting with 
historical controls of unprotected stenting (and thus 
might have been confounded by a learning curve eﬀ ect) 
or were prone to selection bias. The results of the ICSS-
MRI study are in agreement with two small randomised 
studies in which non-signiﬁ cant increases in the risk of 
cerebral ischaemia on DWI were reported after ﬁ lter-
protected stenting compared with unprotected stenting.22,23 
Together, these ﬁ ndings cast doubt on the eﬃ  cacy of the 
routine use of ﬁ lter-type cerebral protection devices in 
preventing cerebral embolism during stenting. 
Embolisation might develop during insertion of cerebral 
protection devices, especially in tortuous vessels and 
stenoses, which are diﬃ  cult to pass, and thrombo-
embolism might result from damage to the endothelium. 
Nevertheless, some patients might beneﬁ t more than 
others from the use of ﬁ lter-type cerebral protection 
devices, as suggested by a recent DWI study.24 A 
randomised trial comparing protected versus unprotected 
stenting is required to investigate the safety and eﬃ  cacy 
of cerebral protection devices.
Only 17% of DWI lesions in the stenting group and 53% 
in the endarterectomy group were associated with signal 
changes on FLAIR imaging 1 month later. This might be 
because full recovery of tissue injury occurred in the other 
lesions or because of diﬀ erences in slice positioning 
between post-treatment scans and 1-month follow-up 
scans. However, more patients in the stenting group than 
in the endarterectomy group had at least one early DWI 
lesion leading to persistent tissue change. The ﬁ nding of 
a higher proportion of DWI lesions after endarterectomy 
than stenting associated with permanent tissue damage 
on FLAIR might be explained by diﬀ erences in volumes 
of individual lesions but might also suggest diﬀ erent 
pathogenetic mechanisms of cerebral ischaemia between 
stenting and endarterectomy. 
New ischaemic lesions, even without corresponding 
focal deﬁ cit, might lead to clinical consequences in the 
Figure 4: Meta-analysis of studies comparing ischaemic lesions on DWI after carotid stenting versus carotid endarterectomy
Mantel-Haenszel ﬁ xed eﬀ ect model comparing the proportions of patients with hyperintense DWI lesions after stenting versus endarterectomy in nine non-
randomised studies, and in the ICSS-MRI study. Data are numbers of patients with new DWI lesions on post-treatment scans (DWI positive) and total numbers of 
patients in studies. Squares and horizontal lines are odds ratios (OR) and 95% CIs, with size of squares representing study weight. Diamonds represent aggregate OR 
and 95% CI. DWI=diﬀ usion-weighted imaging.
Carotid stenting
DWI positive Total
Carotid endarterectomy OR (95% CI)
DWI positive Total
Favours carotid stenting
0·01 0·1 1 10 100
Favours carotid endarterectomy
Non-randomised studies
Garcia-Sanchez 20049 4 10 1 10 6·00 (0·53–67·65)
Flach 20048 9 21 2 23 7·88 (1·46–42·61)
Roh 200510 8 22 1 26 14·29 (1·62–126·30)
Poppert 200612 22 41 16 93 5·57 (2·46–12·61)
Iihara 200611 32 92 13 139 5·17 (2·53–10·56)
Lacroix 200714 26 61 7 60 5·62 (2·20–14·36)
Faraglia 200713 12 35 3 40 6·43 (1·64–25·27)
Tedesco 200715 24 34 1 30 69·60 (8·31–583·10)
Skjelland 200916 6 28 2 30 3·82 (0·70–20·79)
Subtotal (95% CI) 143 344 46 451 6·71 (4·57–9·87)
Heterogeneity: χ2=6·43, df=8 (p=0·60); I2=0%
Test for overall eﬀect: Z=9·69 (p<0·00001)
Randomised studies
ICSS-MRI study 62 124 18 107 4·94 (2·67–9·16)
 
Total (95% CI) 205 468 64 558 6·16 (4·45–8·54)
Heterogeneity: χ2=6·78, df=9 (p=0·66); I2=0%
Test for overall eﬀect: Z=10·92 (p<0·00001)
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long term, including cognitive decline and dementia.25 
The eﬀ ect of DWI lesions on cognitive function has been 
investigated in a single centre participating in the ICSS-
MRI study and will be the subject of a separate report. 
This study has several limitations. Although allocation 
of treatment was randomised, only 74% of patients 
randomly assigned treatment in ICSS at participating 
centres entered the ICSS-MRI study, 83% of whom 
completed post-treatment scanning. Thus, imbalances 
in unmeasured risk factors for DWI lesions between 
treatment groups might have inﬂ uenced the results. 
Fewer patients allocated to have endarterectomy than to 
stenting completed the MRI study, suggesting a more 
restricted access to neuroimaging from surgical wards 
than from neurological wards. Clinically unstable 
patients with a higher risk for procedural ischaemia 
might have been less likely to complete the imaging 
protocol. However, any such bias is unlikely to explain 
the large diﬀ erence in the occurrence of cerebral 
ischaemia between the two groups. The use of cerebral 
protection devices was not randomised in ICSS, and 
other centre-related factors (eg, experience of the 
interventionalist) might have contributed to the observed 
interaction. Also, because all cerebral protection devices 
used in the ICSS-MRI study were of the ﬁ lter type, we 
cannot make any conclusions about the eﬃ  cacy of other 
types of devices (eg, with distal or proximal balloon 
occlusion). Almost a third of patients in the ICSS-MRI 
study were studied in a 3 Tesla scanner and, although 
there was a higher DWI lesion detection rate than with 
1·5 Tesla, there was no diﬀ erence in the proportion of 
patients analysed with the higher magnetic ﬁ eld strength 
between the two treatment groups. The results were, 
therefore, probably not biased by detection of lesions at 
diﬀ erent ﬁ eld strengths.
By use of a separate masked assessment of MRI, we 
have shown in this substudy that the increased risk of 
cerebral ischaemia after stenting compared with 
endarterectomy reported in ICSS is unlikely to have been 
caused by ascertainment bias. DWI could be used as a 
surrogate outcome measure for treatment safety in future 
pilot studies of carotid interventions.
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